August 07, 2025 a 01:00 pm
ABBV: Analysts Ratings - AbbVie Inc.
AbbVie Inc. has shown a mixed pattern in analyst ratings over the past months. While there is notable stability in overall buy recommendations, the sentiment has shifted slightly towards more hold ratings. This could indicate caution among analysts, possibly due to market conditions or company-specific developments.
Historical Stock Grades
The latest data for AbbVie Inc. as of August 2025 highlights a modest shift in analyst sentiment with a total count of 27 ratings. The distribution indicates a strong buy sentiment maintaining a consistent outlook with no signals of sell pressure.
| Rating Category | Number of Recommendations | Score Visualization |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 13 | |
| Hold | 11 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Analyzing the months leading to August 2025 reveals subtle shifts in sentiment. While the number of Strong Buy recommendations has diminished slightly from early 2024, Hold ratings have seen an uptick.
- The total number of ratings has remained fairly consistent, fluctuating mildly between 26 to 29.
- There has been a noticeable decline in Strong Buy ratings, while Hold ratings increased, indicating a cautious stance by analysts.
Percentage Trends
The proportional analysis of ratings over the past year highlights a clear trend towards more conservative ratings. As Strong Buy ratings decreased, the percentage of Hold ratings saw an increase.
- Strong Buy recommendations constituted about 33% in late 2024 but have decreased to approximately 11% by August 2025.
- The Hold recommendations have grown from 16% in late 2024 to about 41% currently, suggesting increased caution among analysts.
- This shift points towards a more conservative forecast as buy sentiments have subdued and hold sentiments have grown.
Latest Analyst Recommendations
The latest recommendations provide insight into the prevailing sentiment on AbbVie Inc., with a general maintenance in outlook by major rating companies:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-01 | Overweight | Overweight | Morgan Stanley |
| 2025-08-01 | Buy | Buy | Guggenheim |
| 2025-08-01 | Outperform | Outperform | Raymond James |
| 2025-05-14 | Neutral | Buy | Citigroup |
| 2025-04-29 | Buy | Buy | Guggenheim |
Analyst Recommendations with Change of Opinion
Changes in analyst opinions indicate adjustments based on evolving market conditions and internal company performance:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-14 | Neutral | Buy | Citigroup |
| 2024-11-22 | Outperform | Market Perform | Leerink Partners |
| 2024-11-04 | Buy | Hold | Argus Research |
| 2024-06-05 | Buy | Hold | HSBC |
| 2024-01-29 | Outperform | Market Perform | William Blair |
Interpretation
The current analysis of AbbVie Inc. indicates a stable market perception with a moderate degree of caution emerging among analysts. The decline in Strong Buy ratings and increase in Hold ratings suggest a measured outlook as analysts adjust to evolving market conditions. However, the absence of Sell recommendations points to continued confidence in the stock's underlying value. This consistent pattern reflects steady trust but growing prudence due to potential uncertainties.
Conclusion
AbbVie Inc. is currently viewed with cautious optimism by the analyst community. While there is substantial confidence in maintaining its position, shifts towards Hold ratings indicate a wait-and-see approach. This could be driven by broader economic trends or sector-specific challenges. The stock remains fundamentally strong, with persistent buy recommendations reflecting potential for growth. However, analysts are seemingly hedging against unforeseen market volatility by issuing more neutral ratings. This balanced perspective suggests awareness both of existing opportunities and potential risks in the market.